Global Leading Market Research Publisher QYResearch announces the release of its latest report "18F-FDG (Fluorodeoxyglucose) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global 18F-FDG (Fluorodeoxyglucose) market, including market size, share, demand, industry development status, and forecasts for the next few years.

For nuclear medicine physicians, oncologists, and diagnostic imaging specialists, accurate detection and staging of malignant tumors requires radiopharmaceuticals that can visualize metabolic activity at the cellular level. The global 18F-FDG (Fluorodeoxyglucose) market addresses this need through a positron-emitting radiopharmaceutical containing no carrier and radioactive 2-deoxy-2-fluoro-D-glucose, administered via intravenous injection for use with positron emission tomography (PET). Since malignant tumor cells metabolize glucose much more rapidly than normal cells, the radionuclide fluorine [18F] labeled on deoxy sugar participates in cell metabolism, enabling PET-CT to capture abnormal glucose metabolism and detect tumor activity. 18F-FDG is suitable for early tumor diagnosis, staging, and treatment evaluation.

The global market for 18F-FDG (Fluorodeoxyglucose) was estimated to be worth US$ 822 million in 2025 and is projected to reach US$ 1820 million, growing at a CAGR of 12.2% from 2026 to 2032. This robust growth reflects increasing PET-CT equipment adoption, particularly in China, and expanding oncology diagnostic applications.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6093404/18f-fdg--fluorodeoxyglucose

PET Tracer for Metabolic Imaging of Malignant Tumors
18F-FDG (Fluorodeoxyglucose) is a positron-emitting radiopharmaceutical that contains no carrier and radioactive 2-deoxy-2-fluoro-D-glucose. It can be combined with positron emission tomography (PET) for diagnostic purposes. It is administered by intravenous injection. Glucose is one of the metabolic energy substances of the human body. Malignant tumor cells have a strong metabolism and metabolize glucose much more than normal cells. The radionuclide fluorine [18F] is labeled on deoxy sugar (DG), and its properties are basically the same as glucose and participate in cell metabolism. Using PET-CT to capture the 18F-FDG sugar metabolism of human tissue can detect the activity of tumor cells. The positron β+ emitted by the decay of 18FDG quickly collides with electrons to annihilate, emitting a pair of photons with equal energy (511keV) and opposite directions.

The short half-life (109.8 minutes) requires on-site or nearby cyclotron production and rapid distribution. 18F-FDG is suitable for PET imaging to evaluate abnormal glucose metabolism, assisting in evaluation of malignant tumors in patients with known or suspected abnormalities. Applications include early diagnosis, staging, and treatment evaluation.

Industry Segmentation: Concentration Levels & Applications
The 18F-FDG market is segmented by radioactive concentration and clinical application:

Normal Concentration (0.37 - 0.74 GBq/ml): Standard dose for routine oncology PET imaging. A major cancer center reported using normal concentration 18F-FDG for over 10,000 oncology PET scans annually.

High Concentration (0.74 - 1.5 GBq/ml): Higher dose for larger patients or imaging protocols requiring increased signal-to-noise ratio.

Ultra-high Concentration (1.5 - 4.5 GBq/ml): Specialized dose for high-throughput PET centers or specific research protocols.

Application Segments
Oncology (PET): Tumor detection, staging, restaging, and treatment response monitoring (chemotherapy, radiation, immunotherapy). A leading oncology hospital reported that 18F-FDG PET-CT changed treatment management in 30% of cancer patients.

Coronary Heart Disease (PET): Myocardial viability assessment to guide revascularization decisions.

Neuropsychiatric Diseases (PET): Alzheimer's disease, epilepsy, and movement disorder evaluation.

Others: Inflammation and infection imaging.

Technology Developments & Market Trends
Over the past six months, several advancements have shaped the market. Automated synthesis modules have improved 18F-FDG production consistency and reduced operator radiation exposure. Quality control innovations (rapid HPLC, TLC) accelerate lot release. Extended stability formulations enable distribution to more remote PET centers.

As China's medical level improves, the number of PET-CT equipment will continue to increase, thereby further releasing demand for 18F-FDG. The trend toward total-body PET scanners increases tracer demand per patient. Theranostics expansion (diagnostic plus therapeutic radiopharmaceuticals) drives cyclotron production capacity investment. Reimbursement for PET imaging varies by country, affecting market growth rates.

Regional Market Dynamics
North America leads the 18F-FDG market, driven by high PET-CT installed base, favorable reimbursement for oncology imaging, and strong radiopharmacy distribution networks. The United States dominates with significant oncology PET volumes.

Europe follows closely, with strong nuclear medicine infrastructure in Germany, France, and Italy. Asia-Pacific is the fastest-growing region, with rapidly increasing PET-CT installations in China, Japan, South Korea, and India, and government healthcare investment.

Competitive Landscape
Key players include Siemens Healthineers (PETNET Solutions), Atulaya Healthcare, Elysia, Primo Biotechnology, SOFIE, Shyzkx, Dongcheng Pharmaceutical (Andike), China Isotope & Radiation Corporation (HTA Co., Ltd.), and Huayitec.

Market Segmentation
The 18F-FDG (Fluorodeoxyglucose) market is segmented as below:

By Company

Siemens Healthineers (PETNET Solutions)

Atulaya Healthcare

Elysia

Primo Biotechnology

SOFIE

Shyzkx

Dongcheng Pharmaceutical (Andike)

China Isotope & Radiation Corporation (HTA Co., Ltd.)

Huayitec

Segment by Concentration

Normal Concentration (0.37 - 0.74 GBq/ml)

High Concentration (0.74 - 1.5 GBq/ml)

Ultra-high Concentration (1.5 - 4.5 GBq/ml)

Segment by Application

Oncology (PET)

Coronary Heart Disease (PET)

Neuropsychiatric Diseases (PET)

Others

Exclusive Industry Outlook
Looking ahead, the convergence of 18F-FDG technology with novel PET tracers, total-body PET scanners, and theranostics represents a steady growth opportunity. Development of next-generation 18F-FDG analogs with improved tumor uptake may enhance diagnostic accuracy. Integration with artificial intelligence for PET image analysis will improve interpretation consistency. Additionally, the expansion of PET-CT into emerging markets and theranostic centers will drive sustained demand. The ability to offer 18F-FDG that combines consistent radiochemical purity, reliable supply, and regulatory compliance—supported by cyclotron production and distribution networks—will define competitive differentiation.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp